# A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

> **NCT03445013** · PHASE1 · COMPLETED · sponsor: **Novan, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** SB414 6%
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT03445013
- **Lead sponsor:** Novan, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-13
- **Primary completion:** 2018-01-31
- **Final completion:** 2018-02-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2018-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03445013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03445013, "A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03445013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*